A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

Breast Cancer Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00087620
• Other study ID #: ML17771
• Status: Terminated
• Phase: Phase 4
• First received: July 12, 2004
• Last updated: February 2, 2017
• Start date: September 2004
• Est. completion date: October 2004

Study information

• Verified date: February 2017
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed sequentially by docetaxel (75 mg/m2 i.v. D1 Q3W).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. completion date: October 2004
• Est. primary completion date: October 2004
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have provided written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice

• Be female and at least 18 years of age. Note: must be 19 years of age if the patient is a resident of the state of Alabama

• Be ambulatory (outpatient) and have a Karnofsky performance status of more than 70%

• Have confirmed breast cancer with locally advanced and/or metastases

• Have at least one site with defined tumor

• Have met one of the study definitions of primary or nonprimary resistance to an anthracycline-containing therapy

Exclusion Criteria:

• Pregnant/lactating women

• Women of childbearing potential with either a positive or no pregnancy test

• Women of childbearing potential unless using a reliable and appropriate contraceptive method (Postmenopausal women must have not had their period for at least 12 months to be considered of non-childbearing potential)

• Prior treatment with chemotherapy in the advanced/metastatic setting

• HER 2/neu positive status without prior treatment with trastuzumab

• Prior treatment with IV bolus 5-FU, continuous 5-FU infusion, capecitabine or other oral fluoropyrimidines

• Prior treatment with a taxane if less than 12 months passed from the time of therapy completion to relapse

• Mitomycin C or nitrosoureas within 6 weeks preceding treatment start

• Organ allografts requiring immunosuppressive therapy

• Radiotherapy to the skeleton within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiotherapy

• Hormonal therapy within 10 days preceding study treatment start

• Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery

• Blood transfusions/growth factors to aid hematologic recovery within 2 weeks prior to study treatment start

• Participation in any investigational drug study within 4 weeks preceding treatment start

• Prior unanticipated severe reaction to fluoropyrimidine therapy

• Known hypersensitivity to 5-fluorouracil, taxanes or any of the components of capecitabine

• Requirement for concurrent use of the antiviral agent sorivudine or chemically related analogues

• Evidence of CNS metastases

• History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma

• Clinically significant (i.e. active) cardiac disease

• Abnormal laboratory values

• Severe renal impairment

• Serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease

• Lack of physical integrity of the upper GI tract

• Life expectancy of less than 3 months

• Unwilling/unable to comply with the protocol

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• XELODA [capecitabine]

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

United States,